https://nova.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 Personalizing First-Line Systemic Therapy in Metastatic Colorectal Cancer: Is There a Role for Initial Low-Intensity Therapy in 2021 and Beyond? A Perspective From Members of the Australasian Gastrointestinal Trials Group https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:50027 Wed 28 Jun 2023 09:28:42 AEST ]]> Patterns of Relapse in Australian Patients With Clinical Stage 1 Testicular Cancer: Utility of the Australian and New Zealand Urogenital and Prostate Cancer Trials Group Surveillance Recommendations https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:53996 Wed 28 Feb 2024 16:39:56 AEDT ]]> Lynch syndrome testing of colorectal cancer patients in a high-income country with universal healthcare: a retrospective study of current practice and gaps in seven australian hospitals https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51759 70 years). Of 38 patients with high-risk tumour test results and genetics services referral, diagnostic testing was carried out for 25 (89%) and identified a LS pathogenic/likely pathogenic variant for 11 patients (44% of 25; 0.7% of 1,624 patients). Conclusions: Given the LS testing and referral gaps, further work is needed to identify strategies for successful integration of LS testing into clinical care, and provide a model for hereditary cancers and broader genomic medicine. Standardised reporting may help clinicians interpret tumour test results and initiate further actions.]]> Wed 13 Mar 2024 08:10:01 AEDT ]]> Real-World Outcomes in Patients With Brain Metastases Secondary to HER2-Positive Breast Cancer: An Australian Multi-centre Registry-based Study https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:52763 Tue 14 Nov 2023 15:23:12 AEDT ]]>